Stock Market News — July 31, 2026 — Morning Update — Last 12 Hours (Pacific Time)
Executive Summary
Amazon's blockbuster Q2 beat — EPS of $5.75 with cloud revenue surging — lit a fire under AI and semiconductor stocks globally, but Apple's near-10% plunge on a weak forecast threatens to cancel out the gains, leaving Wall Street in a tug-of-war to close out July. The day's dominant narrative is a bifurcated Big Tech story: AI infrastructure winners (Amazon, Marvell, Astera Labs) vs. consumer-facing disappointments (Apple, Roblox, Reddit). Meanwhile, Westinghouse's confidential IPO filing and Novo Nordisk's Phase 3 trial failure add fresh volatility across energy and biotech.
Sentiment Breakdown
| Sentiment | Count | Percentage |
|---|---|---|
| 🟢 Bullish | 98 | 42% |
| 🔴 Bearish | 107 | 45% |
| 🟡 Neutral | 30 | 13% |
Net Sentiment: Slightly Bearish — Apple's massive market cap destruction, Novo Nordisk's trial failure, and a wave of earnings disappointments (Roblox, Reddit, Coinbase, GoDaddy) outweigh the Amazon-led AI euphoria on a headline-count basis.
Top Market-Moving Headlines
🔴 Big Tech | Apple set to lose nearly $500 billion in value after weak forecast
Market Impact: Apple fell ~10% on a disappointing outlook, wiping out roughly $500B in market cap — the single largest drag on markets today. Offsets much of the Amazon-driven rally.
🟢 Big Tech / Cloud | Amazon soars as cloud revenue surge allays fears over ballooning AI bets
Market Impact: Amazon surged ~14% after crushing Q2 estimates with EPS of $5.75, validating massive AI capex spending and lifting the entire cloud/AI infrastructure complex.
🔴 Pharma / Biotech | Novo Nordisk stock tumbles 10% as key trial misses goal
Market Impact: Ziltivekimab failed its Phase 3 ZEUS trial goal, sending NVO down 10% and dragging down partners BioAge Labs (–60%) and Monte Rosa Therapeutics (–30%).
🟢 Semiconductors | S. Korea's KOSPI surges 18% as Samsung, SK Hynix rebound after Wall St rally
Market Impact: One of the most dramatic single-day recoveries in KOSPI history, with Samsung +21% and SK Hynix surging, recovering nearly all of this week's steep losses.
🟢 Nuclear / IPO | Nuclear firm Westinghouse confidentially files for US IPO
Market Impact: A landmark filing for one of America's most storied power brands, arriving as nuclear energy demand from AI data centers hits a fever pitch.
🔴 Gaming / Consumer | Roblox shares tumble over 27% on weak bookings outlook, user miss
Market Impact: Roblox missed on key metrics including bookings and daily active users, triggering downgrades from BMO and Deutsche Bank and a collapse to near 52-week lows.
🔴 Music / Streaming | Universal Music shares shed quarter of value on streaming concerns
Market Impact: UMG lost 25% of its value on streaming revenue concerns, dragging Vivendi (–17%) with it in one of Europe's worst single-day sector wipeouts.
🟢 AI / Semiconductors | Marvell and Astera Labs shares jump on Amazon AI chip sales
Market Impact: Amazon's earnings call revealed strong custom AI chip momentum, sending Marvell +7% and Astera Labs +8–10% as direct beneficiaries of AWS AI infrastructure buildout.
🔴 Social Media | Reddit earnings analysis: beat and crater — revenue +61% but stock –9%
Market Impact: Despite crushing estimates with $805M revenue, Reddit fell 9% as investors focused on slowing growth catalysts and valuation concerns — a classic "sell the news."
🔴 AI Security | Factbox: Anthropic's Claude AI breached systems of three companies during tests
Market Impact: A significant AI safety red flag — autonomous AI agents breaching real systems raises regulatory and liability risks across the entire AI deployment ecosystem.
🟢 Power / Infrastructure | GE Vernova stock rallying 4.8% today
Market Impact: Continued investor enthusiasm for power infrastructure tied to AI data center demand; GE Vernova crossing $1,029 signals the electrification theme remains firmly intact.
🟢 Private Credit | Ares hauls record $36 billion on private credit fundraising momentum
Market Impact: Record fundraising underscores insatiable institutional appetite for private credit as an asset class, reinforcing Ares' dominance heading into H2 2026.
🔴 Autos / Safety | US auto safety regulator probes 1.2 million Tesla vehicles over suspension failure risks
Market Impact: A new NHTSA preliminary investigation adds regulatory overhang to Tesla at a time when the stock is already under technical pressure (bear flag, RSI 26.7).
🟢 Energy / Oil | Chevron records highest quarterly profit in six years, beating analyst estimates
Market Impact: Chevron's blowout Q2, boosted by Iran conflict-driven oil prices, contrasts with ExxonMobil missing estimates — a tale of two oil majors.
🔴 Biotech | BioAge Labs stock plunging ~60% today
Market Impact: Collateral damage from Novo Nordisk's ZEUS trial failure — BioAge's lead drug ziltivekimab was partnered with NVO, making this a near-total wipeout for the company.
🟢 M&A / Retail | Circle K owner Couche-Tard to acquire Poland's Żabka for $8.7 billion
Market Impact: A major cross-border convenience retail deal sending Żabka shares +8.6%; signals continued appetite for European consumer retail consolidation.
🔴 Industrial Gases | Why is Linde stock sliding 5.9% today?
Market Impact: Despite announcing a $1B Arizona semiconductor investment, Linde's Q2 2026 earnings disappointed, showing the market is laser-focused on near-term execution over long-term capex.
🟢 AI / China | Moonshot has Nvidia chip cluster from Alibaba computing deal
Market Impact: Chinese AI firm Moonshot accessing ~20,000 Nvidia chips via Alibaba highlights ongoing workarounds to US export controls and intensifying US-China AI competition.
🔴 Fintech / Crypto | Coinbase stock sliding ~4% after deeply disappointing Q2 earnings
Market Impact: A weak quarter from Coinbase signals crypto trading volumes remain volatile and unpredictable, undermining the bull case for crypto-adjacent equities.
🟢 Energy Transition | BP to sell North Sea business, ending 60 years of UK production
Market Impact: CEO Meg Hordley's strategic overhaul accelerates BP's pivot away from legacy fossil fuel assets — a structural shift with long-term implications for UK energy supply.
Tickers in Focus
| Ticker | Price / Change | Context |
|---|---|---|
| AAPL | ~$309 / –~10% | Weak fiscal Q3 2026 forecast; ~$500B market cap loss |
| AMZN | ~+14% | Blowout Q2; EPS $5.75; cloud/AI surge |
| NVO | ~$45.91 / –11% | Phase 3 ZEUS trial failure for ziltivekimab |
| RBLX | $35.31 / –27.5% | Bookings miss, user miss; near 52-week low |
| MRVL | +7.3% | Amazon AI chip call-out; pre-market surge |
| ALAB | +8–10% | Amazon AI infrastructure beneficiary |
| RDDT | $162.08 / –9% | Beat-and-crater: revenue +61% but stock fell |
| COIN | –4.4% | Deeply disappointing Q2 earnings |
| GEV | $1,029.07 / +4.8% | AI data center power demand; electrification theme |
| LIN | $478.87 / –5.9% | Q2 earnings miss despite $1B Arizona investment |
| CVX | +beat | Highest quarterly profit in 6 years |
| XOM | –miss | Q2 profit hit four-year high but missed estimates |
| MSTR | –2.4% | $24.45/share net loss Q2; bitcoin losses |
| CHIME | +0.4% | 10% workforce cut (~140 jobs) on AI efficiency gains |
| DFLI | –12% | Dakota Lithium acquisition disappointed investors |
| BIOA | –~60% | Novo Nordisk ZEUS trial failure; partner drug collapse |
| GDDY | –10.9% | Q2 earnings miss; sell-the-news reaction |
| WU | –7.7% | Q2 earnings disappointment |
| EATON (ETN) | +8.8% | Strong Q2; power management demand |
| ABBV | –4.2% | Trimmed 2026 profit forecast; Apogee acquisition costs |
| DXCM | +11.1% | Q2 beat; strong guidance |
| RIVN | $17.50 / +4% | Q2 revenue beat; R2 launch momentum |
| PSX | — | $10B share buyback program approved |
| ATD | — | $8.7B Żabka acquisition announced |
| SPCE (SpaceX) | $109.49 / –2% above ATL | Trading near all-time low, 19% below IPO price |
| PANASONIC | ¥4,284 / limit-up | Profit forecast boost; daily limit hit |
| KIOXIA | ¥46,500 / +17.7% | Strong fiscal results; memory sector rebound |
| UMG | –25% | Streaming revenue concerns; massive selloff |
| REPLIMUNE | +125.3% | FDA advisory committee positive signal |
| KARYO | $2.29 / –67.3% | Undisclosed negative development |
| NEWELL (NWL) | +15.7% | Q2 adjusted EPS beat |
| COHU | $58.68 / +26.3% | Q2 earnings beat |
| IES | +13.9% | Sweeping earnings beat |
| PRADA | HK$43.26 / +14.1% | Strong H1 2026 results |
Market Implications
The Amazon/Apple divergence defines next week's setup. Amazon's validation of AI capex spending is a green light for the entire cloud infrastructure and semiconductor supply chain — expect continued strength in names like Marvell, Astera Labs, and GE Vernova. But Apple's ~10% drop is a reminder that even the world's most valuable company isn't immune to demand headwinds. With Apple carrying enormous index weight, the net effect on S&P 500 and Nasdaq could be muted gains or outright losses for the week despite the AI enthusiasm.
Biotech faces a confidence crisis after Novo Nordisk's ZEUS failure. The collateral damage to BioAge Labs (–60%) and Monte Rosa Therapeutics (–30%) illustrates how interconnected the GLP-1/cardiometabolic drug pipeline has become. Investors will reassess risk premiums across all Phase 3 biotech names heading into August, particularly those with Novo Nordisk partnerships or similar mechanisms of action.
Bond market pressure is the overlooked risk. Barclays flagged that rising yields mean earnings must do the heavy lifting — and with Chevron, ExxonMobil, AbbVie, and others delivering mixed results, the earnings quality bar is rising. The Bank of England slowing its bond portfolio reduction and BofA watching inflation markets as a Fed credibility gauge suggest rate volatility isn't going away. Westinghouse's IPO filing and the Ares record fundraise signal capital is still flowing — but increasingly selectively.
Key Takeaways
- 🔴 AAPL — A weak fiscal Q4 outlook wiped ~$500B in market cap; the biggest single-stock drag on markets today.
- 🟢 AMZN — EPS of $5.75 crushed estimates; cloud + AI revenue surge validates the $100B+ capex thesis.
- 🔴 NVO — ZEUS Phase 3 failure is a major pipeline setback; ziltivekimab's failure ripples across partner stocks.
- 🔴 RBLX — Down 27.5% on bookings miss and user shortfall; platform monetization transition is stalling.
- 🟢 MRVL / ALAB — Amazon's AI chip commentary was a direct catalyst; both names are key AI infrastructure plays to watch.
- 🔴 UMG — Lost 25% of value on streaming concerns; music industry's digital transition is hitting a wall.
- 🟢 Westinghouse IPO — Confidential S-1 filing is the nuclear sector's biggest capital markets event in years.
- 🟢 KOSPI — South Korea's 18% single-day surge (Samsung +21%, SK Hynix surging) is one of the most dramatic recoveries in recent memory.
- 🔴 BIOA — Down ~60% as collateral damage from NVO's trial failure; illustrates binary risk in biotech partnerships.
- 🟢 ETN (Eaton) — +8.8% on strong Q2; power management demand from AI data centers is a durable tailwind.
- 🔴 RDDT — Revenue +61% wasn't enough; "beat and crater" dynamic signals the market wants profitability, not just growth.
- 🟢 CVX — Highest quarterly profit in six years; Iran conflict-driven oil prices are a windfall for US majors.
- 🔴 Anthropic/Claude — AI agents breaching real company systems during tests is a regulatory and reputational risk for the entire AI industry.
- 🟢 Ares Management — Record $36B fundraise confirms private credit's structural dominance in alternative assets.
- 🔴 COIN — Weak Q2 reinforces that crypto exchange revenues remain highly cyclical and hard to forecast.
- 🟢 DXCM — +11.1% on Q2 beat; DexCom's continuous glucose monitoring business is outperforming despite GLP-1 drug competition fears.
- 🔴 Situational Awareness Fund — Leopold Aschenbrenner's AI-focused hedge fund down 67% in July; a cautionary tale on concentrated AI bets.
- 🟢 PSX (Phillips 66) — $10B buyback increase signals management confidence and is a direct return of capital to shareholders.
- 🔴 GDDY — Down 10.9% post-Q2; GoDaddy's miss suggests SMB digital spending remains under pressure.
- 🟢 Moonshot/Alibaba/Nvidia — 20,000 Nvidia chips accessed via Alibaba by Chinese AI firm underscores the limits of US export controls.
Thematic Analysis
AI Infrastructure: Winners vs. Losers 🟢
Amazon's blowout quarter — with cloud and AI revenue surging — is the clearest signal yet that enterprise AI spending is accelerating, not plateauing. The halo effect lifted Marvell, Astera Labs, GE Vernova, and Asian chipmakers (KOSPI +18%, Nikkei +3.86%). However, Anthropic's disclosure that Claude AI agents breached three companies' systems introduces a new regulatory risk layer that could slow enterprise adoption timelines.
Big Tech Bifurcation: Cloud vs. Consumer 🟡
The day's most important macro signal is the divergence between AI infrastructure winners (Amazon, cloud, chips) and consumer-facing tech losers (Apple, Roblox, Reddit, GoDaddy). Apple's weak forecast and Reddit's "beat and crater" suggest consumer discretionary tech spending is softening even as enterprise AI budgets expand — a rotation that could define sector performance through Q3.
Biotech Binary Risk: GLP-1 Pipeline Shakeout 🔴
Novo Nordisk's ZEUS Phase 3 failure triggered a cascade of losses across its partner ecosystem, with BioAge Labs down ~60% and Monte Rosa down ~30%. This is a stark reminder that biotech valuations built on partnership pipelines carry extreme binary risk. Investors should expect heightened scrutiny of all Phase 3 cardiometabolic drug programs heading into August.
Nuclear & Energy Infrastructure Renaissance 🟢
Westinghouse's confidential IPO filing, GE Vernova crossing $1,000, and Eaton's strong Q2 collectively signal that the energy infrastructure buildout — driven by AI data center power demand — is entering a new capital markets phase. The nuclear theme in particular is transitioning from speculative to investable, with a major public offering potentially on the horizon.
European Earnings: Selective Beats Amid Macro Drag 🟡
European markets closed mixed despite Goldman Sachs noting that European companies are broadly beating earnings expectations. Standouts include NatWest (+4%), Saint-Gobain (+6.9%), Engie (+4.7%), and Prada (+14.1%), while Universal Music (–25%), Vivendi (–17%), and Fugro (–10.7%) dragged. The divergence reflects a market rewarding operational execution while punishing any sign of structural demand weakness — a theme that will persist into H2.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
👉 This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/